Imágenes de páginas
PDF
EPUB

(7) to enter into such contracts, leases, cooperative agreements, or other transactions, without regard to section 529 of Title 31 and section 5 of Title 41, as may be necessary in the conduct of his functions, with any public agency, or with any person, firm, association, corporation, or educational institution; and

(8) to take necessary action to insure that all channels for the dissemination and exchange of scientific knowledge and information are maintained between the National Cancer Institute and the other scientific, medical, and biomedical disciplines and organizations nationally and internationally.

(July 1, 1944, ch. 373, title IV, § 410, as added Dec. 23, 1971, Pub. L. 92–218, § 3(a), 85 Stat. 782.)

EFFECTIVE DATE

Section effective 60 days after Dec. 23, 1971, or on such prior date after Dec. 23, 1971, as the President shall prescribe and publish in the Federal Register, see section 7 of Pub. L. 92-218, set out as a note under section 286a of this title.

§ 286e. Scientific review: use of peer review groups; reports to Congress.

(a) The Director of the National Cancer Institute shall, by regulation, provide for proper scientific review of all research grants and programs over which he has authority (1) by utilizing, to the maximum extent possible, appropriate peer review groups established within the National Institutes of Health and composed principally of non-Federal scientists and other experts in the scientific and disease fields, and (2) when appropriate, by establishing, with the approval of the National Cancer Advisory Board and the Director of the National Institutes of Health, other formal peer review groups as may be required.

(b) The Director of the National Cancer Institute shall, as soon as practicable after the end of each calendar year, prepare in consultation with the National Cancer Advisory Board and submit to the President for transmittal to the Congress a report on the activities, progress, and accomplishments under the National Cancer Program during the preceding calendar year and a plan for the Program during the next five years. (July 1, 1944, ch. 373, title IV, § 410A, as added Dec. 23, 1971, Pub. L. 92–218, § 3(a), 85 Stat. 782.)

EFFECTIVE Date

Section effective 60 days after Dec. 23, 1971, or on such prior date after Dec. 23, 1971, as the President shall prescribe and publish in the Federal Register, see section 7 of Pub. L. 92-218, set out as a note under section 286a of this title.

§ 286f. National Cancer Advisory Board.

(a) Membership; representation of interests; qualifications of appointees.

There is established in the National Cancer Institute a National Cancer Advisory Board (hereinafter in this section referred to as the "Board") to be composed of twenty-three members as follows:

(1) The Secretary, the Director of the Office of Science and Technology, the Director of the National Institutes of Health, the chief medical officer of the Veterans' Administration (or his designee), and a medical officer designated by the Secretary of Defense shall be ex officio members of the Board.

[blocks in formation]

Not more than twelve of the appointed members of the Board shall be scientists or physicians and not more than eight of the appointed members shall be representatives from the general public. The scientists and physicians appointed to the Board shall be appointed from persons who are among the leading scientific or medical authorities outstanding in the study, diagnosis, or treatment of cancer or in fields related thereto. Each appointed member of the Board shall be appointed from among persons who by virtue of their training, experience, and background are especially qualified to appraise the programs of the National Cancer Institute.

(b) Terms; quorum; National Cancer Advisory Board supersedure of National Advisory Cancer Council. (1) Appointed members shall be appointed for sixyear terms, except that of the members first appointed six shall be appointed for a term of two years, and six shall be appointed for a term of four years, as designated by the President at the time of appointment.

(2) Any member appointed to fill a vacancy occurring prior to expiration of the term for which his predecessor was appointed shall serve only for the remainder of such term. Appointed members shall be eligible for reappointment and may serve after the expiration of their terms until their successors have taken office.

(3) A vacancy in the Board shall not affect its activities, and twelve members thereof shall constitute a quorum.

(4) The Board shall supersede the existing National Advisory Cancer Council, and the appointed members of the Council serving on the effective date of this section shall serve as additional members of the Board for the duration of their terms then existing, or for such shorter time as the President may prescribe.

(c) Chairman.

The President shall designate one of the appointed members to serve as Chairman for a term of two years.

(d) Meetings; advisory and auxiliary functions.

The Board shall meet at the call of the Director of the National Cancer Institute or the Chairman, but not less often than four times a year and shall advise and assist the Director of the National Cancer Institute with respect to the National Cancer Program.

(e) Executive Secretary.

The Director of the National Cancer Institute shall designate a member of the staff of the Institute to act as Executive Secretary of the Board.

(f) Investigation of programs and activities; hearings; testimony; time and place for convening and acting.

The Board may hold such hearings, take such testimony, and sit and act at such times and places as the Board deems advisable to investigate programs and activities of the National Cancer Program.

(g) Reports to President and Congress.

The Board shall submit a report to the President for transmittal to the Congress not later than Janu

ary 31 of each year on the progress of the National Cancer Program toward the accomplishment of its objectives.

(h) Compensation and travel expenses.

Members of the Board who are not officers or employees of the United States shall receive for each day they are engaged in the performance of the duties of the Board compensation at rates not to exceed the daily equivalent of the annual rate in effect for GS-18 of the General Schedule, including traveltime; and all members, while so serving away from their homes or regular places of business, may be allowed travel expenses, including per diem in lieu of subsistence, in the same manner as such expenses are authorized by section 5703 of Title 5, for persons in the Government service employed intermittently. (i) Staff, information, and other assistance.

The Director of the National Cancer Institute shall make available to the Board such staff, information, and other assistance as it may require to carry out its activities. (July 1, 1944, ch. 373, title IV, § 410B, as added Dec. 23, 1971, Pub. L. 92-218, § 3 (a), 85 Stat. 783.)

REFERENCES IN TEXT

For effective date of this section, referred to in subsec. (b) (4), see Effective Date note set out under this section. The General Schedule, referred to in subsec. (h), is set out under section 5332 of Title 5, Government Organization and Employees.

EFFECTIVE DATE

Notwithstanding provision for effectiveness of Pub. L. 92-218 60 days after Dec. 23, 1971, or on such prior date after Dec. 23, 1971, as the President shall prescribe and publish in the Federal Register, members of National Cancer Advisory Board may be appointed at any time after Dec. 23, 1971 and compensated from the date of first taking office as provided in this section 7(a) and (c) of Pub. L. 92-218, set out as a note under section 286a of this title.

TRANSFER OF FUNCTIONS

All functions vested by law in the Office of Science and Technology and in the Director or Deputy Director of the Office of Science and Technology were transferred to the Director of the National Science Foundation, and Office of Science and Technology, including the offices of Director and Deputy Director, provided for by sections 1 and 2 of 1962 Reorg. Plan No. 2, was abolished by sections 2 and 3(a) (5) of 1973 Reorg. Plan No. 1, effective July 1, 1973, set out in the Appendix to Title 5, Government Organization and Employees.

§ 286g. Authorization of appropriations.

For the purpose of carrying out this part (other than section 286c of this title), there are authorized to be appropriated $400,000,000 for the fiscal year ending June 30, 1972, $500,000,000 for the fiscal year ending June 30, 1973; and $600,000,000 for the fiscal year ending June 30, 1974. (July 1, 1944, ch. 373, title IV, 410C, as added Dec. 23, 1971, Pub. L. 92-218, § 3(a), 85 Stat. 784.)

EFFECTIVE DATE

Section effective 60 days after Dec. 23, 1971, or on such prior date after Dec. 23, 1971, as the President shall prescribe and publish in the Federal Register, see section 7 of Pub. L. 92-218, set out as a note under section 286a of this title.

PART B.-NATIONAL HEART AND LUNG INSTITUTE

AMENDMENTS

1972-Pub. L. 92-423, § 6(e), Sept. 19, 1972, 86 Stat. 687, substituted "Heart and Lung" for "Heart" in the Part B heading.

§ 287. Establishment of Institute.

There is established in the Public Health Service a National Heart and Lung Institute (hereafter in this part referred to as the "Institute"). (As amended Sept. 19, 1972, Pub. L. 92-423, § 6(a), 86 Stat. 686.) AMENDMENTS

1972-Pub. L. 92-423 substituted "National Heart and Lung Institute" for "National Heart Institute".

EFFECTIVE DATE OF 1972 AMENDMENT Section 9 of Pub. L. 92-423 provided that: "This Act and the amendments made by this Act [see Short Title note under this section] shall take effect sixty days after the date of enactment of this Act [Sept. 19, 1972], or on such prior date after the date of enactment of this Act [Sept. 19, 1972], as the President shall prescribe and publish in the Federal Register."

SHORT TITLE OF 1972 AMENDMENT

Section 1 of Pub. L. 92-423 provided that: "This Act [which enacted sections 287b-287f and 2871 of this title, amended sections 218, 241, 287, 287a, 287g, and 287h of this title, and enacted provisions set out as notes under this section] may be cited as the 'National Heart, Blood Vessel, Lung, and Blood Act of 1972'."

CONGRESSIONAL FINDINGS AND DECLARATION OF PURPOSE Section 2 of Pub. L. 92-423 provided that: "(a) Congress finds and declares that

"(1) diseases of the heart and blood vessels collectively cause more than half of all the deaths each year in the United States and the combined effect of the disabilities and deaths from such diseases is having a major social and economic impact on the Nation;

"(2) elimination of heart and blood vessel diseases as significant causes of disability and death could increase the average American's life expectancy by about eleven years and could provide for annual savings to the economy in lost wages, productivity, and costs of medical care of more than $30,000,000,000 per year;

"(3) chronic lung diseases have been gaining steadily in recent years as important causes of disability and death, with emphysema alone being the fastest rising cause of death in the United States;

"(4) chronic respiratory diseases affect an estimated ten million Americans, emphysema an estimated one million, chronic bronchitis an estimated four million, and asthma an estimated five million;

"(5) thrombosis (the formation of blood clots in the vessels) may cause, directly or in combination with other problems, many deaths and disabilities from heart disease and stroke which can now be prevented;

"(6) blood and blood products are essential human resources whose value in saving life and promoting health cannot be assessed in terms of dollars;

"(7) the provision of prompt and effective emergency medical services utilizing to the fullest extent possible advances in transportation and communications and other electronic systems and specially trained professional and paraprofessional health care personnel can reduce substantially the number of fatalities and severe disabilities due to critical illnesses in connection with heart, blood vessel, lung, and blood diseases; and

"(8) the greatest potential for advancement against heart, blood vessel, lung, and blood diseases lies in the National Heart and Lung Institute, but advancement against such diseases depends not only on the research programs of that Institute but also on the research programs of other research institutes of the National Institutes of Health.

"(b) It is the purpose of this Act [see Short Title note under this section] to enlarge the authority of the National Heart and Lung Institute in order to advance the national attack upon heart, blood vessel, lung, and blood diseases."

REPORT TO CONGRESS

Section 8 of Pub. L. 92-423 provided that: "The Secretary of Health, Education, and Welfare shall carry out a review of all administrative processes under which the National Heart, Blood Vessel, Lung, and Blood Disease

Program, established under part B of title IV of the Public Health Service Act [this part], will operate, including the processes of advisory council and peer group reviews, in order to assure the most expeditious accomplishment of the objectives of the Program. Within one year of the date of enactment of this Act [Sept. 19, 1972], the Secretary shall submit a report to the Congress of the findings of such review and the actions taken to facilitate the conduct of the Program, together with recommendations for any needed legislative changes."

§ 287a. Research and training in diseases of the heart, blood vessels, lung, and blood.

In carrying out the purposes of section 241 of this title with respect to heart, blood vessel, lung, and blood diseases the Secretary, through the Institute and in cooperation with the National Heart and Lung Advisory Council (hereinafter in this part referred to as the "Council"), shall—

(1) Fosterage of research.

Conduct, assist, and foster researches, investigations, experiments, and demonstrations relating to the cause, prevention, and methods of diagnosis and treatment of heart, blood vessel, lung, and blood diseases;

(2) Coordination of research and control programs. Promote the coordination of research and control programs conducted by the Institute, and similar programs conducted by other agencies, organizations, and individuals;

(3) Research facilities made available.

Make available research facilities of the Service to appropriate public authorities, and to health officials and scientists engaged in special studies related to the purposes of this part;

(4) Grants-in-aid for research projects.

Make grants-in-aid to universities, hospitals, laboratories, and other public or private agencies and institutions, and to individuals for such research projects relating to heart, blood vessel, lung, and blood diseases as are recommended by the Council, including grants to such agencies and institutions for the construction, acquisition, leasing, equipment, and maintenance of such hospital, clinic, laboratory, and related facilities, and for the care of such patients therein, as are necessary for such research;

(5) Establishment of information center.

Establish an information center on research, prevention, diagnosis, and treatment of heart, blood vessel, lung, and blood diseases, and collect and make available, through publications and other appropriate means, information as to, and the practical application of, research and other activities carried on pursuant to this part;

(6) Securement of expert advice and services.

Secure from time to time, and for such periods as he deems advisable, the assistance and advice of persons from the United States or abroad who are experts in the field of heart, blood vessel, lung, and blood diseases;

(7) Establishment of fellowships and traineeships.

In accordance with regulations and from funds appropriated or donated for the purpose (1) establish and maintain research fellowships in the Insti

tute and elsewhere with such stipends and allowances (including travel and subsistence expenses) as he may deem necessary to train research workers and procure the assistance of the most brilliant and promising research fellows from the United States and abroad, and, in addition, provide for such fellowships through grants, upon recommendation of the Council, to public and other nonprofit institutions; and (2) provide training and instruction and establish and maintain traineeships, in the Institute and elsewhere in matters relating to the diagnosis, prevention, and treatment of heart, blood vessel, lung, and blood diseases with such stipends and allowances (including travel and subsistence expenses) for trainees as he may deem necessary, the number of persons receiving such training and instruction, and the number of persons holding such traineeships, to be fixed by the Council, and, in addition, provide for such training, instruction, and traineeships through grants, upon recommendation of the Council, to public and other nonprofit institutions. (As amended Spet. 19, 1972, Pub. L. 92-423, § 6(b), 86 Stat. 686.)

AMENDMENTS

1972-Pub. L. 92-423 substituted "heart, blood vessel, lung, and blood" for "heart" wherever appearing in introductory text and pars. (1) and (4)-(7), formerly designated pars. (a) and (d)-(g); substituted "Secretary" and "National Heart and Lung Advisory Council" for "Surgeon General" and "National Advisory Heart Council" in introductory text; and redesignated as pars. (1)-(7) former pars. (a)–(g), respectively.

EFFECTIVE DATE OF 1972 AMENDMENT

Amendment by Pub. L. 92-423 effective 60 days after Sept. 19, 1972, or on such prior date after Sept. 19, 1972, as the President shall prescribe and publish in the Federal Register, see section 9 of Pub. L. 92-423, set out as a note under section 287 of this title.

SECTION REFERRED TO IN OTHER SECTIONS

This section is referred to in section 287g, 287h of this title.

§ 287b. National heart, blood vessel, lung, and blood disease program.

(a) Plan development; National Institutes of Health and National Institute of Neurological Diseases and Stroke, coordination provision.

The Director of the Institute, with the advice of the Council, shall develop a plan for a National Heart, Blood Vessel, Lung, and Blood Disease Program (hereafter in this part referred to as the "Program") to expand, intensify, and coordinate the activities of the Institute respecting heart, blood vessel, lung, and blood diseases (including its activities under section 287a of this title) and shall carry out the Program in accordance with such plan. The Program shall be coordinated with the other research institutes of the National Institutes of Health to the extent that they have responsibilities respecting such diseases and shall provide for

(1) investigation into the epidemiology, etiology, and prevention of all forms and aspects of heart, blood vessel, lung, and blood diseases, including investigations into the social, environmental, behavioral, nutritional, biological, and genetic determinants and influences involved in the epidemiology, etiology, and prevention of such diseases;

(2) studies and research into the basic biological processes and mechanisms involved in the under

lying normal and abnormal heart, blood vessel, lung, and blood phenomena;

(3) research into the development, trial, and evaluation of techniques, drugs, and devices, (including computers) used in, and approaches to, the diagnosis, treatment (including emergency medical service), and prevention of heart, blood vessel, lung, and blood diseases and the rehabilitation of patients suffering from such diseases;

(4) establishment of programs that will focus and apply scientific and technological efforts involving biological, physical, and engineering sciences to all facets of heart, blood vessel, lung, and blood diseases with emphasis on refinement, development, and evaluation of technological devices that will assist, replace, or monitor vital organs and improve instrumentation for detection, diagnosis, and treatment of those diseases;

(5) establishment of programs for the conduct and direction of field studies, large-scale testing and evaluation, and demonstration of preventive, diagnostic, therapeutic, and rehabilitative approaches to, and emergency medical services for, such diseases;

(6) studies and research into blood diseases and blood, and into the use of blood for clinical purposes and all aspects of the management of its resources in this country, including the collection, preservation, fractionalization, and distribution of it and its products;

(7) the education and training of scientists, clinicians, and educators, in fields and specialties (including computer sciences) requisite to the conduct of programs respecting heart, blood vessel, lung, and blood diseases;

(8) public and professional education relating to all aspects of such diseases and the use of blood and blood products and the management of blood resources;

(9) establishment of programs for study and research into heart, blood vessel, lung, and blood diseases of children (including cystic fibrosis, hyaline membrane, and hemolytic and hemophilic diseases) and for the development and demonstration of diagnostic, treatment, and preventive approaches to these diseases; and

(10) establishment of programs for study, research, development, demonstrations and evaluation of emergency medical services for people who become critically ill in connection with heart, blood vessel, lung, or blood diseases, which programs shall include programs for (A) the training of paraprofessionals in (i) emergency treatment procedures, and (ii) utilization and operation of emergency medical equipment, (B) the development and operation of (i) mobile critical care units (including helicopters and other airborne units where appropriate), (ii) radio, telecommunications, and other means of communications and (iii) electronic monitoring systems, and (C) the coordination with other community services and agencies in the joint use of all forms of emergency vehicles, communications systems, and other appropriate services.

The Program shall give special emphasis to the continued development in the Institute of programs

relating to atherosclerosis, hypertension, thrombosis, and congenital abnormalities of the blood vessels as causes of stroke, and to effective coordination of such programs with related stroke programs in the National Institute of Neurological Diseases and Stroke. (b) Transmittal of plan and report to Congress.

(1) The plan required by subsection (a) of this section shall (A) be developed within one hundred and eighty days after the effective date of this section, (B) be transmitted to the Congress, and (C) set out the Institute's staff requirements to carry out the Program and recommendations for appropriations for the Program.

(2) The Director of the Institute shall, as soon as practicable after the end of each calendar year, prepare in consultation with the Council and submit to the President for transmittal to the Congress a report on the activities, progress, and accomplishments under the Program during the preceding calendar year and a plan for the Program during the next five years.

(c) Director of the Institute; functions.

In carrying out the Program, the Director of the Institute, under policies established by the Director of the National Institutes of Health and after consultation with the Council and without regard to any other provision of this chapter, may

(1) if authorized by the Council, obtain (in accordance with section 3109 of Title 5, but without regard to the limitation in such section on the number of days or the period of such service) the services of not more than fifty experts or consultants who have scientific or professional qualifications;

(2) acquire, construct, improve, repair, operate, and maintain heart, blood vessel, lung, and blood disease laboratory, research, training, and other necessary facilities and equipment, and related accommodations as may be necessary, and such other real or personal property (including patents) as the Director deems necessary; and acquire, without regard to section 34 of Title 40, by lease or otherwise, through the Administrator of General Services, buildings or parts of buildings in the District of Columbia or communities located adjacent to the District of Columbia for the use of the Institute for a period not to exceed ten years; and (3) enter into such contracts, leases, cooperative agreements, or other transactions, without regard to section 529 of Title 31 and section 5 of Title 41, as may be necessary in the conduct of his functions, with any public agency, or with any person, firm, association, corporation, or educational institution.

(d) Assistant Director for Health Information Programs; appointment; functions; special emphasis of program.

There shall be in the Institute an Assistant Director for Health Information Programs who shall be appointed by the Director of the Institute. The Director of the Institute, acting through the Assistant Director for Health Information Programs, shall conduct a program to provide the public and the health professions with health information with regard to cardiovascular and pulmonary diseases.

In the conduct of such program, special emphasis shall be placed upon dissemination of information regarding diet, exercise, stress, hypertension, cigarette smoking, weight control, and other factors affecting the prevention of arteriosclerosis and other cardiovascular diseases and of pulmonary diseases. (July 1, 1944, ch. 373, title IV, § 413, as added Sept. 19, 1972, Pub. L. 92-423, § 3(3), 86 Stat. 680.)

REFERENCES IN TEXT

For effective date of this section, referred to in subsec. (b) (1) (A), see Effective Date note set out under this section.

CODIFICATION

A prior section 287b, act July 1, 1944, ch. 373, title IV, § 413, as added June 16, 1948, ch. 481, § 3(b) 62 Stat. 464, and amended 1953 Reorg. Plan No. 1, §§ 5, 8, eff. April 11, 1953, 18 F.R. 2053, 67 Stat. 631, provided for administration of powers by Surgeon General, acceptance of gifts, and memorials, and is now covered by section 287h of this title. EFFECTIVE DATE

Section effective 60 days after Sept. 19, 1972, or on such prior date after Sept. 19, 1972, as the President shall prescribe and publish in the Federal Register, see section 9 of Pub. L. 92-423, set out as a note under section 287 of this title.

SECTION REFERRED TO IN OTHER SECTIONS

This section is referred to in section 287g of this title.

§ 287c. Heart, blood vessel, lung, and blood disease prevention and control programs.

(a) Establishment.

The Director of the Institute, under policies established by the Director of the National Institutes of Health and after consultation with the Council, shall establish programs as necessary for cooperation with other Federal Health agencies, State, local, and regional public health agencies, and nonprofit private health agencies in the diagnosis, prevention, and treatment (including the provision of emergency medical services) of heart, blood vessel, lung, and blood diseases, appropriately emphasizing the prevention, diagnosis, and treatment of such diseases of children.

(b) Authorization of appropriations.

There is authorized to be appropriated to carry out this section $25,000,000 for the fiscal year ending June 30, 1973, $35,000,000 for the fiscal year ending June 30, 1974, and $45,000,000 for the fiscal year ending June 30, 1975. (July 1, 1944, ch. 373, title IV, § 414, as added Sept. 19, 1972, Pub. L. 92-423, § 3(3), 86 Stat. 682.)

CODIFICATION

A prior section 287c, act July 1, 1944, ch. 373, title IV, § 414, as added June 16, 1948, c. 481, § 3 (b), 62 Stat. 464, provided for the functions of the Council, and is now covered by section 287g of this title.

EFFECTIVE DATE

Section effective 60 days after Sept. 19, 1972, or on such prior date after Sept. 19, 1972, as the President shall prescribe and publish in the Federal Register, see section 9 of Pub. L. 92-423, set out as a note under section 287 of this title.

SECTION REFERRED TO IN OTHER SECTIONS This section is referred to in section 2871 of this title. § 287d. National research and demonstration centers for heart, blood vessel, lung, and blood diseases.

(a) Research, training, demonstration, and disease prevention activities.

(1) The Director of the Institute may provide for the development of

(A) fifteen new centers for basic and clinical research into, training in, and demonstration of, advanced diagnostic, prevention, and treatment methods (including methods of providing emergency medical services) for heart, blood vessel, and blood diseases; and

(B) fifteen new centers for basic and clinical research into, training in, and demonstration of, advanced diagnostic, prevention, and treatment methods (including methods of providing emergency medical services) for chronic lung diseases (including bronchitis, emphysema, asthma, cystic fibrosis, and other lung diseases of children). (2) The centers developed under paragraph (1) (A) shall, in addition to being utilized for research, training, and demonstrations, be utilized for the following prevention programs for cardiovascular diseases:

(A) Programs to develop improved methods of detecting individuals with a high risk of developing cardiovascular disease.

(B) Programs to develop improved methods of intervention against those factors which cause individuals to have a high risk of developing such disease.

(C) Programs to develop health professions and allied health professions personnel highly skilled in the prevention of such disease.

(D) Programs to develop improved methods of providing emergency medical services for persons with such disease.

(3) Centers developed under this subsection may be supported under subsection (b) of this section or under any other applicable provision of law. The research, training, and demonstration activities carried out through any such center may relate to any one or more of the diseases referred to in paragraph (1) of this subsection.

(b) Payments under cooperative agreements with public or nonprofit agencies; use of funds; limitations; "construction" defined.

The Director of the Institute, under policies established by the Director of the National Institutes of Health and after consultation with the Council, may enter into cooperative agreements with public or nonprofit private agencies or institutions to pay all or part of the cost of planning, establishing, or strengthening, and providing basic operating support for, existing or new centers (including centers established under subsection (a) of this section) for basic or clinical research into, training in, and demonstration of, advanced diagnostic, prevention, and treatment methods for heart, blood vessel, lung, or blood diseases. Funds paid to centers under cooperative agreements under this subsection may be used for

(1) construction, notwithstanding section 285 of this title,

(2) staffing and other basic operating costs, including such patient care costs as are required for research,

(3) training, including training for allied health professions personnel, and

(4) demonstration purposes.

The aggregate of payments (other than payments for construction) made to any center under such

« AnteriorContinuar »